# Evaluation of MAF-1217 in Patients With DED

> **NCT03833882** · NA · COMPLETED · sponsor: **VISUfarma SpA** · enrollment: 72 (actual)

## Conditions studied

- Evaporative Dry Eye Disease

## Interventions

- **DEVICE:** MAF1217
- **OTHER:** Cationorm

## Key facts

- **NCT ID:** NCT03833882
- **Lead sponsor:** VISUfarma SpA
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-27
- **Primary completion:** 2019-06-19
- **Final completion:** 2019-06-19
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2019-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03833882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03833882, "Evaluation of MAF-1217 in Patients With DED". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03833882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*